UK Biotechs Present Novel Technologies at BioTrinity 2017
Biotechnology Rolls on Despite Brexit Uncertainty
Avoiding Costly Errors in Bioassay Development
Developers Have a Range of Options When Optimizing Bioassays for Biologics
Screening Innovations and 3D Cell Culture Assay Developments
Showcased at ELRIG
New Tech Aids Drug Discovery
In Scientific Publishing, Sharing Is Caring
The Saga for Open-Access Research Continues
For full access to this article login to GEN Select now.
Points to Consider in Choosing a CRO
Knowing When to Rely on In-House Capabilities and When to Outsource Is Critical to Success
- The pressure to develop new drugs that are best in class within strict budgets has led most pharma and biotech companies to focus on core research and pipeline development, while outsourcing clinical research. Since 2001, spending by drug sponsors on CROs has grown 15% annually, outpacing the 11% rate ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.